Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · West Pharmaceutical Services (WST)

West Pharmaceutical refinances $130 million in debt with new $750 million credit facility

Neutral Impact 3 of 5 financing

On October 26, 2026, West Pharmaceutical Services entered a new credit agreement with Bank of America as administrative agent. It includes a $750 million revolving facility and a $200 million term loan advanced on the effective date, and the company used the borrowings to repay $130.0 million outstanding under its 2019 credit agreement, which it terminated with no early termination penalties. The filing reports no change to earnings or guidance, but it sets new debt terms, including a maximum net leverage ratio of 3.50 to 1.0.

Key points

  • New credit agreement provides a $750 million revolving facility and a $200 million term loan, with a five-year term from October 26, 2026.
  • $130.0 million outstanding under the 2019 credit agreement was repaid in full on October 26, 2026, with no early termination penalties.
  • Borrowings are unsecured; the net leverage covenant caps the ratio at 3.50 to 1.0, or 4.00 to 1.0 during material acquisition periods.
  • Term loan quarterly amortization starts March 31, 2028, at $1.25 million to $2.5 million per quarter, with the balance due at maturity.

The filing

CompanyWest Pharmaceutical Services (WST)
Form8-K, current report
Filed with the SECOct 26, 2026, 5:14 PM ET
Accession number0000105770-26-000114

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.